NCT00006079View on ClinicalTrials.gov

Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

June 19, 1998

Primary Completion Date

April 27, 2004

Study Completion Date

April 27, 2004

Conditions
Cervical CancerPrecancerous Condition
Interventions
DRUG

Eflornithine

Arm I-II: Patients receive one of two different doses of oral eflornithine daily for 28 days.

OTHER

Placebo

Patients receive oral placebo daily for 28 days.

Trial Locations (1)

77030

University of Texas - MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER